背景:有忧郁症(L.)Dunal,被称为Ashwagandha,长期以来一直用于阿育吠陀的传统医学,印度,有代表性的适应原。睡花的主要活性成分是内酯,根通常被用作具有广泛药理活性的药物,可以用来治疗失眠,神经衰弱,糖尿病和皮肤癌。
目的:对睡眠水份进行全成分定性和定量分析。我们探索了适应原代表植物W.somnifera对MGO损伤的成纤维细胞衰老事件的改善作用及其作用机制,并验证了WS可以抑制AGEs的积累并调节ECM组分之间的动态平衡的假设。通过调节整合素β1受体的表达;因此,WS将细胞行为和生物学功能维持在正常范围内,并从细胞水平延缓皮肤老化。
方法:在本研究中,首先通过HPLC指纹图谱和LC-MS检测对WS的成分进行定性和定量分析。第二,建立了MGO诱导的CML过表达成纤维细胞损伤模型。ELISA法检测CML表达及关键细胞外基质ECM蛋白成分COL1、FN1、LM5和TNC合成的合成;CCK-8法检测细胞活力;EDU法检测细胞增殖能力;荧光法检测细胞粘附能力;迁移试验法检测细胞迁移能力;qRT-PCR法检测调控途径TGF-β1和2、MMP-9的表达;用荧光法检测ECMs法检测NITC法,TWM法TGF-β1、MMP-2、MMP-9和ITGB1。
结果:总计,从WS分析了27种活性成分,主要由乙醇化物成分组成,基于MGO诱导的成纤维细胞衰老损伤模型,WS显著抑制CML合成。通过上调整合素β1的表达,上调TGF-β1基因的表达,这与ECM的产生密切相关,下调MMP-2和MMP-9基因的表达,这与ECM的降解密切相关,保持了四种ECM的动态平衡,提高细胞活力和增殖,迁移和粘附能力。
结论:WS可以通过减少CML的积累来预防细胞行为功能障碍和延缓皮肤衰老,上调ITGB1受体的表达,维持ECM-整合素受体相互作用的正常功能,并防止ECM蛋白质成分的产生和降解之间的不平衡。这项研究报告的结果表明,作为CML抑制剂,WS可以调节ECM-整合素的稳态,并且在延缓衰老领域具有巨大的潜力。
BACKGROUND: Withania somnifera (L.) Dunal, known as Ashwagandha, has long been used in traditional medicine in Ayurveda, India, a representative
adaptogen. The main active constituents of W. somnifera are withanolides, and the root is often used as a medicine with a wide range of pharmacological activities, which can be used to treat insomnia, neurasthenia, diabetes mellitus and skin cancer.
OBJECTIVE: Whole-component qualitative and quantitative analyses were performed on W. somnifera. We explored the ameliorative effect of the
adaptogen representative plant W. somnifera on the senescence events of MGO-injured fibroblasts and its action mechanism and verified the hypotheses that WS can inhibit the accumulation of AGEs and regulate the dynamic balance among the components of the ECM by modulating the expression of integrin β1 receptor; as a result, WS maintains cellular behavioural and biological functions in a normal range and retards the aging of skin from the cellular level.
METHODS: In this study, the components of WS were first qualitatively and quantitatively analysed by HPLC fingerprinting and LC-MS detection. Second, a model of MGO-induced injury of CML-overexpressing fibroblasts was established. ELISA was used to detect CML expression and the synthesis of key extracellular matrix ECM protein components COL1, FN1, LM5 and TNC synthesis; CCK-8 was used to detect cell viability; EDU was used to detect cell proliferation capacity; fluorescence was used to detect cell adhesion capacity; and migration assay were used to detect cell migration capacity; qRT-PCR was used to detect the regulatory pathway TGF-β1 and MMP-2, MMP-9 in ECMs; immunofluorescence was used to detect the expression of ITGB1; and WB was used to detect the expression of COL1, FN1, LM5, Tnc, TGF-β1, MMP-2, MMP-9 and ITGB1.
RESULTS: In total, 27 active ingredients were analysed from WS, which mainly consisted of withanolide components, such as withaferin A and withanolide A. Based on the model of MGO-induced fibroblast senescence injury, WS significantly inhibited CML synthesis. By up-regulating the expression of integrin β1, it upregulated the expression of the TGF-β1 gene, which is closely related to the generation of ECMs, downregulated the expression of the MMP-2 and MMP-9 genes, which are closely related to the degradation of ECMs, maintained the dynamic balance of the four types of ECMs, and improved cell viability as well as proliferation, migration and adhesion abilities.
CONCLUSIONS: WS can prevent cellular behavioural dysfunction and delay skin ageing by reducing the accumulation of CML, upregulating the expression of the ITGB1 receptor, maintaining the normal function of ECM-integrin receptor interaction and preventing an imbalance between the production and degradation of protein components of ECMs. The findings reported in this study suggest that WS as a CML inhibitor can modulate ECM-integrin homeostasis and has great potential in the field of aging retardation.